Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib hydrochloride + irinotecan + docetaxel
- Development stage
- Unknown
- Lead developer
- Hangzhou First People's Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is an investigational combination chemotherapy and targeted therapy regimen being evaluated for the second-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). The regimen consists of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit; irinotecan, a topoisomerase I inhibitor; and docetaxel, a taxane that stabilizes microtubules. This specific combination is being studied in a Phase 2 clinical trial (NCT04757779) sponsored by the First People's Hospital of Hangzhou for patients who have relapsed after first-line platinum-based chemotherapy. In the trial, anlotinib is administered orally, while irinotecan or docetaxel are administered intravenously as separate treatment arms.
- Other names
- anlotinib + irinotecan + docetaxelanlotinib hydrochloride combined with irinotecan or docetaxelAL3818 + CPT-11 + docetaxel
02
Targets
TOP1 (DNA Topoisomerase I)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on anlotinib hydrochloride + irinotecan + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib hydrochloride + irinotecan + docetaxel.